Targeted Cancer Drug Could Delay Bone Tumor Progression
Patients with refractory osteosarcoma saw a 67% reduction in the risk of disease progression in a new Phase 3 study.
Updated on Oct. 26, 2026 in Cancer
Live Poll
Do you believe pharmaceutical companies are successfully prioritizing the development of treatments for rare cancers?
The experimental drug ris-rez significantly delayed disease progression in patients with relapsed refractory osteosarcoma compared to chemotherapy. The findings offer a potential new path for patients who have exhausted at least two previous lines of treatment.
Why it matters
For patients with advanced, treatment-resistant bone cancer, these results suggest an alternative to standard chemotherapy that may improve time without disease progression. This development comes as the industry seeks more effective targeted options for rare, hard-to-treat solid tumors.
A Phase 3 trial of 122 patients aged 12 and older with relapsed refractory osteosarcoma found that ris-rez led to a median of 5.5 months without disease worsening, compared to 1.4 months for those receiving chemotherapy. The experimental therapy demonstrated a 67% reduction in the risk of disease progression or death.
The players
GSK
A global pharmaceutical company focused on developing therapies for oncology, immunology, and infectious diseases.
Hansoh Pharmaceutical
A research-driven pharmaceutical firm that collaborates on the development of novel cancer treatments.
The details
The drug functions as a targeted therapy designed to deliver cell-killing agents directly to tumor cells, aiming to bypass the broader toxicity often associated with conventional chemotherapy. In this late-stage study, patients received a 12-milligram dose every three weeks to compare efficacy against standard care. By focusing on specific cancer cell mechanisms, the therapy seeks to extend the period of disease stability in patients whose cancer has returned after multiple prior interventions.
Timeline
October 26, 2026: Trial results were presented at a medical meeting in Madrid.
Health Landscape
This development represents a major effort by the manufacturer to rebuild its position within the competitive oncology treatment market. It follows a significant increase in research activity, evidenced by the 21 data abstracts presented by the firm at this year's congress compared to 11 last year.
Patients and families navigating refractory osteosarcoma should discuss these study findings with their oncology team to determine if experimental trial participation or future availability aligns with their care plan. Because these results are specific to a late-stage population, individual suitability depends on prior treatment history and clinical status.
The takeaway
The study suggests that targeted therapy could provide a meaningful interval of disease stability for patients who have exhausted traditional options. Patients should keep track of their treatment milestones and maintain a detailed record of previous therapy responses to facilitate discussions with their physician.
Further reading
For more information on evolving treatments for bone-related malignancies, visit the Cancer section.
Live Poll
Do you believe pharmaceutical companies are successfully prioritizing the development of treatments for rare cancers?
